Celyad Oncology Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.71	4.2	7	12.45	30.02
Cash & Short-Term Investments	1.71	4.2	7	12.45	30.02
Cash Growth	-59.33%	-40.03%	-43.72%	-58.54%	74.18%
Accounts Receivable	0.75	0.8	2.72	1.12	2.06
Inventory	-	0.42	-	-	-
Other Current Assets	1.04	1.1	1.4	1.26	2.21
Total Current Assets	3.5	6.52	11.12	14.83	34.29
Net Property, Plant & Equipment	-	1.49	1.83	0.31	3.25
Other Intangible Assets	0.02	0.41	0.39	0.86	36.17
Other Long-Term Assets	0.78	1.52	2.94	3.72	6.24
Total Assets	4.3	9.93	16.28	19.72	79.94
Accounts Payable	0.51	1.23	1.24	4.75	6.61
Accrued Expenses	0.56	0.79	0.94	5.1	5.95
Current Portion of Long-Term Debt	0.62	0.64	0.37	0.44	0.36
Current Portion of Leases	-	0.14	0.16	0.14	0.9
Unearned Revenue	0.03	0.05	0.23	-	-
Other Current Liabilities	0.1	-	-	-	-
Total Current Liabilities	1.82	2.85	2.93	10.43	13.83
Long-Term Debt	-	4.2	4.51	4.58	5.85
Long-Term Leases	-	0.76	0.9	0.12	1.73
Other Long-Term Liabilities	0.04	1.61	1.64	0.27	14.9
Total Long-Term Liabilities	0.04	6.57	7.05	4.97	22.48
Total Liabilities	1.86	9.42	9.98	15.4	36.3
Common Stock	9.22	8.22	32.95	78.59	78.59
Additional Paid-in Capital	320.73	320.73	295.99	240.88	240.88
Accumulated Other Comprehensive Income	35.86	35.77	35.73	34.8	33.17
Retained Earnings	-363.37	-364.2	-358.37	-349.95	-309
Shareholders' Equity	2.44	0.51	6.3	4.32	43.64
Total Liabilities & Equity	4.3	9.93	16.28	19.72	79.94
Total Debt	0.62	5.74	5.93	5.28	8.85
Net Cash (Debt)	1.09	-1.54	1.08	7.17	21.17
Net Cash Growth	-	-	-85.00%	-66.14%	135.13%
Net Cash Per Share	0.03	-0.04	0.04	0.32	1.36
Book Value	2.44	0.51	6.3	4.32	43.64
Book Value Per Share	0.06	0.01	0.25	0.19	2.80
Tangible Book Value	2.42	0.11	5.91	3.45	7.47
Tangible Book Value Per Share	0.06	0.00	0.23	0.15	0.48